← All Alzamend Neuro, INC filings

Alzamend Neuro, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ALZN
Alzamend Neuro, INC
10-K: Alzamend Neuro Reports FY2026 Results, Focus on AL001 and ALZN002 Trials
Alzamend Neuro, Inc. filed its Form 10-K for the fiscal year ended April 30, 2026, detailing progress in its AL001 and ALZN002 clinical development programs and significant increases in operating expenses.
NASDAQ
ALZN
Alzamend Neuro, INC
10-K: Alzamend Neuro Faces Going Concern Doubts Amidst Clinical Trial Delays and Funding Needs
Alzamend Neuro's latest 10-K filing reveals significant financial challenges, including recurring losses and a going concern opinion, alongside a major delay in its ALZN002 Alzheimer's clinical trial, despite progress with its AL001 program.
NASDAQ
ALZN
Alzamend Neuro, INC
10-K: Alzamend Neuro, Inc. Files 10-K Report Detailing Financials and Clinical Progress
Alzamend Neuro, Inc. has released its annual 10-K report, outlining its financial status, clinical trial progress, and future strategies for developing treatments for Alzheimers, bipolar disorder, major depressive disorder, and PTSD.